Structure Therapeutics Inc. (the “Company”) is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The Company was incorporated in February 2019 in the Cayman Islands, with operating subsidiaries in the United States and China. In June 2022, the Company changed its name from ShouTi Inc. to Structure Therapeutics Inc.
Company profile
Ticker
GPCR
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ShouTi Inc.
SEC CIK
Corporate docs
Subsidiaries
Annapurna Bio Pty Limited • Annapurna Bio, Inc. • Basecamp Bio Hong Kong Limited • Basecamp Bio Inc. • Basecamp Bio USA Inc. • Gasherbrum Bio, Inc. • Lhotse Bio, Inc. • Shanghai Basecamp Biotechnology Co., Ltd. • Shanghai ShouTi Biotechnology Co., Ltd. • ShouTi Hong Kong Limited ...
IRS number
981480821
GPCR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
S-8
Registration of securities for employees
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
8 Mar 24
8-K
Regulation FD Disclosure
18 Dec 23
EFFECT
Notice of effectiveness
30 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
UPLOAD
Letter from SEC
24 Nov 23
S-1
IPO registration
17 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 50.64 mm | 50.64 mm | 50.64 mm | 50.64 mm | 50.64 mm | |
Cash burn (monthly) | (no burn) | 6.32 mm | 8.72 mm | 5.98 mm | 1.69 mm | |
Cash used (since last report) | n/a | 43.49 mm | 59.96 mm | 41.16 mm | 11.64 mm | |
Cash remaining | n/a | 7.14 mm | -9.33 mm | 9.48 mm | 38.99 mm | |
Runway (months of cash) | n/a | 1.1 | -1.1 | 1.6 | 23.0 |
Institutional ownership, Q3 2023
97.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 84 |
Opened positions | 41 |
Closed positions | 6 |
Increased positions | 29 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 1.64 tn |
Total shares | 45.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 12.66 mm | $329.17 mm |
T. Rowe Price | 2.51 mm | $126.07 bn |
Driehaus Capital Management | 2.39 mm | $120.45 bn |
JHG Janus Henderson | 2.09 mm | $97.50 bn |
Deep Track Capital | 1.92 mm | $96.55 bn |
Adage Capital Partners GP, L.L.C. | 1.80 mm | $90.75 bn |
BVF | 1.75 mm | $88.24 bn |
FMR | 1.59 mm | $80.18 bn |
T. Rowe Price Investment Management | 1.57 mm | $78.83 bn |
TCG Crossover Management | 1.50 mm | $75.77 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Xichen Lin | Ordinary Shares | Grant | Acquire A | No | No | 0 | 85,707 | 0.00 | 85,707 |
15 Mar 24 | Xichen Lin | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 35.25 | 213,486 | 7.53 mm | 213,486 |
15 Mar 24 | Yingli Ma | Ordinary Shares | Grant | Acquire A | No | No | 0 | 36,729 | 0.00 | 36,729 |
15 Mar 24 | Yingli Ma | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 35.25 | 91,494 | 3.23 mm | 91,494 |
15 Mar 24 | Mark Allen Bach | Ordinary Shares | Grant | Acquire A | No | No | 0 | 26,235 | 0.00 | 26,235 |
15 Mar 24 | Mark Allen Bach | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 35.25 | 65,352 | 2.30 mm | 65,352 |
15 Mar 24 | Jun Yoon | Ordinary Shares | Grant | Acquire A | No | No | 0 | 59,469 | 0.00 | 1,123,133 |
15 Mar 24 | Jun Yoon | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 35.25 | 148,134 | 5.22 mm | 148,134 |
News
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
18 Apr 24
Cantor Fitzgerald Initiates Coverage On Structure Therapeutics with Overweight Rating, Announces Price Target of $65
9 Apr 24
JMP Securities Reiterates Market Outperform on Structure Therapeutics, Maintains $91 Price Target
8 Mar 24